These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 2950265

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
    Alleva DG, Burger CJ, Elgert KD.
    J Immunol; 1994 Aug 15; 153(4):1674-86. PubMed ID: 8046239
    [Abstract] [Full Text] [Related]

  • 4. The mechanism of tumor growth inhibition by tumor-specific Lyt-1+2-T cells. I. Antitumor effect of Lyt-1+2-T cells depends on the existence of adherent cells.
    Fujiwara H, Takai Y, Sakamoto K, Hamaoka T.
    J Immunol; 1985 Sep 15; 135(3):2187-91. PubMed ID: 3874911
    [Abstract] [Full Text] [Related]

  • 5. Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells.
    Bluestone JA, Lopez C.
    J Natl Cancer Inst; 1979 Nov 15; 63(5):1221-7. PubMed ID: 228106
    [Abstract] [Full Text] [Related]

  • 6. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.
    Bear HD.
    Cancer Res; 1986 Apr 15; 46(4 Pt 1):1805-12. PubMed ID: 2936451
    [Abstract] [Full Text] [Related]

  • 7. Deficient tumor-specific immunity in old mice: in vivo mediation by suppressor cells, and correction of the defect by interleukin 2 supplementation in vitro but not in vivo.
    Bruley-Rosset M, Payelle B.
    Eur J Immunol; 1987 Mar 15; 17(3):307-12. PubMed ID: 2952510
    [Abstract] [Full Text] [Related]

  • 8. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 15; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 9. Modification of host antitumor defense mechanisms in mice by progressively growing tumor.
    Maccubbin DL, Mace KF, Ehrke MJ, Mihich E.
    Cancer Res; 1989 Aug 01; 49(15):4216-24. PubMed ID: 2525950
    [Abstract] [Full Text] [Related]

  • 10. Down-regulation of cytotoxic T lymphocyte development by a minor stimulating locus-induced suppressor cascade that involves Lyt-1+ suppressor T cells, IA- macrophages, and their factors.
    Chow KP, Battisto JR.
    J Immunol; 1988 Feb 15; 140(4):1005-13. PubMed ID: 2963857
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2- T cells mediating delayed-type hypersensitivity response and in vivo protective immunity.
    Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H, Kawanishi Y, Tsuchida T, Hamaoka T.
    Jpn J Cancer Res; 1986 Feb 15; 77(2):182-9. PubMed ID: 3082830
    [Abstract] [Full Text] [Related]

  • 13. T cell-mediated immunity to oncornavirus-induced tumors. III. Specific and nonspecific suppression in tumor-bearing mice.
    Plater C, Debré P, Leclerc JC.
    Eur J Immunol; 1981 Jan 15; 11(1):39-44. PubMed ID: 6452278
    [Abstract] [Full Text] [Related]

  • 14. Studies of the mechanisms for the induction of in vivo tumor immunity. IV. Enhancement of the in vitro generation of secondary cell-mediated cytotoxic response by normal peritoneal macrophages and their culture supernatants.
    Igarashi T, Rodrigues D, Ting CC.
    J Immunol; 1979 Apr 15; 122(4):1519-27. PubMed ID: 156217
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Regulation of the in vitro secondary cell-mediated cytotoxic response against syngeneic FBL-3 leukemia by macrophages.
    Igarashi T, Teranishi T, Rodrigues D, Yamamura Y.
    Microbiol Immunol; 1980 Apr 15; 24(6):599-72. PubMed ID: 6968022
    [Abstract] [Full Text] [Related]

  • 17. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
    Nagarkatti M, Toney DM, Nagarkatti PS.
    Cancer Res; 1989 Dec 01; 49(23):6587-92. PubMed ID: 2573418
    [Abstract] [Full Text] [Related]

  • 18. Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression.
    Ting CC, Rodrigues D.
    J Natl Cancer Inst; 1982 Oct 01; 69(4):867-72. PubMed ID: 6214653
    [Abstract] [Full Text] [Related]

  • 19. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
    Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K.
    J Immunol; 1988 Jul 15; 141(2):699-708. PubMed ID: 2968407
    [Abstract] [Full Text] [Related]

  • 20. T-T cell interaction in the induction of delayed-type hypersensitivity (DTH) responses: vaccinia virus-reactive helper T cell activity involved in enhanced in vivo induction of DTH responses and its application to augmentation of tumor-specific DTH responses.
    Takai Y, Kosugi A, Yoshioka T, Tomita S, Fujiwara H, Hamaoka T.
    J Immunol; 1985 Jan 15; 134(1):108-13. PubMed ID: 3155458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.